Zobrazeno 81 - 90
of 211
pro vyhledávání: '"Marco L. Davila"'
Autor:
Matthew J. Riese, K. Venuprasad, Ritesh Kumar, Arianne L. Theiss, Elviche L. Tsakem, Jitendra Kumar, Marco L. Davila, Mahesh Kathania, Amir Kumar Singh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundChimeric antigen receptor (CAR) T-cell therapy is an emerging option for cancer treatment, but its efficacy is limited, especially in solid tumors. This is partly because the CAR T cells become dysfunctional and exhausted in the tumor micro
Autor:
Hany Elmariah, Jongphil Kim, Asmita Mishra, Nicholas J. Lawrence, Marco L. Davila, Bruce R. Blazar, Lia Perez, Kelly Walton, Nelli Bejanyan, Michael Nieder, Brian C. Betts, Harshani R. Lawrence, Elizabeth M. Sagatys, Said M. Sebti, Joseph Pidala, Claudio Anasetti, Rawan Faramand, Shernan G. Holtan, Farhad Khimani, Taiga Nishihori
Publikováno v:
Clin Cancer Res
Purpose: In this first-in-human, phase I, GVHD prevention trial (NCT02891603), we combine pacritinib (PAC), a JAK2 inhibitor, with sirolimus to concurrently reduce T-cell costimulation via mTOR and IL6 activity. We evaluate the safety of pacritinib w
Publikováno v:
Handbook of Hematologic Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5bc9e316fface65fa3279073d345fea
https://doi.org/10.1891/9780826149770.0057
https://doi.org/10.1891/9780826149770.0057
Autor:
Matthew J. Frigault, Philip L. McCarthy, Jorg Dietrich, Shannon L. Maude, David T. Teachey, Stephan A. Grupp, Tom Whitehead, Sara Alexander, Sattva S. Neelapu, Terry J. Fry, Tomas G. Neilan, Marco L. Davila, Elena Mead, Jennifer N. Brudno, Jennifer Holter-Chakrabarty, Claudia Diamonte, Frederick L. Locke, Daniel W. Lee, Bianca Santomasso, Elizabeth J. Shpall, Julie C. Fitzgerald, Krishna V. Komanduri, Marcela V. Maus, Colleen Callahan, Michael R. Bishop, Cameron J. Turtle
Publikováno v:
Journal for immunotherapy of cancer, vol 8, iss 2
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78826d8095d2b25719dcc661bc8a0aef
https://escholarship.org/uc/item/0fj5p33n
https://escholarship.org/uc/item/0fj5p33n
Publikováno v:
Handbook of Hematologic Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62508319198dcd75e57e7f931dd987fd
https://doi.org/10.1891/9780826149770.0055
https://doi.org/10.1891/9780826149770.0055
Autor:
Asmita Mishra, Michael D. Jain, Hien Liu, Joseph Pidala, Hany Elmariah, Xuefeng Wang, Melissa Alsina, Nelli Bejanyan, Aleksandr Lazaryan, Rawan Faramand, Ernesto Ayala, Marco L. Davila, Mohamed A. Kharfan-Dabaja, Michael Nieder, Ram Thapa, Hugo F. Fernandez, Lia Perez, Claudio Anasetti, Frederick L. Locke, L. Ochoa, Farhad Khimani, Taiga Nishihori
Publikováno v:
Blood Adv
The introduction of posttransplant cyclophosphamide (PTCy) made performing allogeneic hematopoietic cell transplantation (HCT) from HLA haplotype–incompatible donors possible. In a setting of PTCy and tacrolimus/mycophenolate mofetil (MMF) as a gra
Autor:
Rawan Faramand, Aliyah Baluch, Julio C. Chavez, Anna E. Coghill, Gabriel S Krivenko, Marco L. Davila, Daniel Ninh, Christina A Bachmeier, Bijal D. Shah, Javier Pinilla-Ibarz, Bhagirathbhai Dholaria, Victoria Larson, Giovanni Grillo, Hien D. Liu, Aleksandr Lazaryan, Jongphil Kim, Elisa Zucchetti, Biwei Cao, Farhad Khimani, Taiga Nishihori, Frederick L. Locke, Jennifer M. Logue, Michael D. Jain
Publikováno v:
Haematologica
CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this
Autor:
Rahul Mhaskar, Bijal D. Shah, Aleksandr Lazaryan, Sameh Gaballa, Marco L. Davila, Christina A Bachmeier, Michael D. Jain, Farhad Khimani, Taiga Nishihori, Julio C. Chavez, Anthony Wood, Frederick L. Locke, Kedar G. Patel, Brian Arciola, Grace Johnson, Ariel Perez Perez
Publikováno v:
Blood. 138:3855-3855
Introduction: Between 50-80% of patients with diffuse large B-cell lymphoma (DLBCL) are cured by frontline (1L) R-CHOP immunochemotherapy. Ultra-high risk (UHR) features for poor overall survival (OS) include: progression through the frontline therap
Autor:
David A. Sallman, Hany Elmariah, Kendra Sweet, Chetasi Talati, Asmita Mishra, Cheryl A Cox, Roshanak Semnani, Rutul R Shah, Helen Sabzevari, Marion Chakiath, Justin Uthuppan, Amy Lankford, Chen Wang, Eric Padron, Andrew T. Kuykendall, Rami S. Komrokji, Jeffrey E. Lancet, Marco L. Davila, Nelli Bejanyan
Publikováno v:
Blood. 138:825-825
Introduction: Therapeutic options for relapsed/refractory (r/r) acute myeloid leukemia (AML) and hypomethylating agent (HMA) failure higher risk myelodysplastic syndrome (MDS) are limited with a median overall survival of < 6 months. Although chimeri
Autor:
Bijal D. Shah, Sameh Gaballa, David Kaldas, Meghan Menges, Marco L. Davila, Kayla Reid, Frederick L. Locke, Michael D. Jain, Julio C. Chavez
Publikováno v:
Blood. 138:2397-2397
Background: Monitoring of peripheral blood (PB) circulating tumor DNA (ctDNA) in DLBCL post axi-cel can risk stratify and predict outcomes in DLBCL (Frank et al, JCO 2021). The utility of monitoring minimal residual disease (MRD) in follicular lympho